SCHEMBL6481850

SCHEMBL6481850

CN1CCC(C(=O)NC(Cc2c[nH]c3ccccc23)C(=O)c2ccc(-c3ccccc3-c3nnn[nH]3)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
ECE1 P42892 1/20 0.45
GHSR Q92847 2/20 0.44
HTR1A P08908 1/20 0.43
HTR1B P28222 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
ITGB2 P05107 1/20 0.41
ICAM1 P05362 1/20 0.41
ITGAL P20701 1/20 0.41
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
GPR84 Q9NQS5 1/20 0.39
SNCA P37840 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481346 0.87 MMP9 (0.43) KMT2ABCHEACHEGPR84SNCA
SCHEMBL6480650 0.82 GHSR (0.51) GHSR
SCHEMBL6482436 0.82 HDAC1 (0.40)
SCHEMBL6483067 0.82 HPGDS (0.44) MEN1KMT2AITGB2ICAM1ITGAL
SCHEMBL6493904 0.80 S1PR1 (0.40) HTR1AHTR1BHTR2AHTR2CHTR2B
SCHEMBL6490489 0.79 MEN1 (0.43) MEN1KMT2AITGB2ICAM1ITGAL
SCHEMBL6492948 0.78 BCHE (0.42) KMT2ABCHEACHEMMP2MMP9
SCHEMBL6488832 0.77 MMP9 (0.43) KMT2AGHSRMMP2MMP9
SCHEMBL6481196 0.77 MMP9 (0.43) KMT2AMMP2MMP9
SCHEMBL6480725 0.76 CA12 (0.42) KMT2AMMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050261332-A1 Sulfonamides and uses thereof ELIXIR PHARMACEUTICALS, INC. 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261332-A1 Sulfonamides and uses thereof GLS2, STS, ABAT MEN1 1857/4885KMT2A 1732/4885ECE1 2907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.